CA2468539C - Delivery of medicaments to the nail - Google Patents
Delivery of medicaments to the nail Download PDFInfo
- Publication number
- CA2468539C CA2468539C CA2468539A CA2468539A CA2468539C CA 2468539 C CA2468539 C CA 2468539C CA 2468539 A CA2468539 A CA 2468539A CA 2468539 A CA2468539 A CA 2468539A CA 2468539 C CA2468539 C CA 2468539C
- Authority
- CA
- Canada
- Prior art keywords
- nail
- medicament
- delivery system
- agent
- etching
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 127
- 210000000282 nail Anatomy 0.000 claims abstract description 177
- 238000005530 etching Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 210000004904 fingernail bed Anatomy 0.000 claims abstract description 14
- 208000031888 Mycoses Diseases 0.000 claims abstract description 10
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 9
- 210000004905 finger nail Anatomy 0.000 claims abstract description 8
- 210000004906 toe nail Anatomy 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 26
- 230000000843 anti-fungal effect Effects 0.000 claims description 24
- 229940121375 antifungal agent Drugs 0.000 claims description 20
- 238000012377 drug delivery Methods 0.000 claims description 19
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 16
- 239000000227 bioadhesive Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 235000002906 tartaric acid Nutrition 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 13
- 239000011975 tartaric acid Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 10
- 229960004125 ketoconazole Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003410 keratolytic agent Substances 0.000 claims description 8
- 229960002962 butenafine Drugs 0.000 claims description 5
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002722 terbinafine Drugs 0.000 claims description 5
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004884 fluconazole Drugs 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- 230000036562 nail growth Effects 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims description 2
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 229960003204 amorolfine Drugs 0.000 claims description 2
- 229960003749 ciclopirox Drugs 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 229960005040 miconazole nitrate Drugs 0.000 claims description 2
- 229960004313 naftifine Drugs 0.000 claims description 2
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 229950005137 saperconazole Drugs 0.000 claims description 2
- 229960000580 terconazole Drugs 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims 1
- 230000001530 keratinolytic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 description 38
- 239000010410 layer Substances 0.000 description 25
- 239000010408 film Substances 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 208000010195 Onychomycosis Diseases 0.000 description 13
- 201000005882 tinea unguium Diseases 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 235000011007 phosphoric acid Nutrition 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 239000003429 antifungal agent Substances 0.000 description 7
- 230000035587 bioadhesion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 102000011782 Keratins Human genes 0.000 description 6
- 108010076876 Keratins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- ZZTCCAPMZLDHFM-UHFFFAOYSA-N ammonium thioglycolate Chemical compound [NH4+].[O-]C(=O)CS ZZTCCAPMZLDHFM-UHFFFAOYSA-N 0.000 description 6
- 229940075861 ammonium thioglycolate Drugs 0.000 description 6
- 229960001631 carbomer Drugs 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- -1 siloxanes Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920000148 Polycarbophil calcium Polymers 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000089 atomic force micrograph Methods 0.000 description 4
- 238000004630 atomic force microscopy Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 229950005134 polycarbophil Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000272534 Struthio camelus Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000012871 anti-fungal composition Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000009474 hot melt extrusion Methods 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028686 Nail avulsion Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000003486 chemical etching Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001907 polarising light microscopy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000005079 FT-Raman Methods 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000002521 compomer Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 208000033511 fungal infection of the toenail Diseases 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229940031576 hydroxypropylbetadex (0.58-0.68 ms) Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Abstract
The present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to surface of the nail. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail. Also included in the present invention are the compositions (i.e., the etching compositions and/or the medicament compositions) used to treat the nail in accordance with the methods of the present invention.
Description
DELIVERY OF MEDICAMENTS TO THE NAIL
Technical Field The technical field to which this invention relates includes the field of delivering medicaments to the human or animal nail. Preferred embodiments of the present invention include a composition and method for the transonychial and perionychial administration of medicaments to the human or animal nail or nail area. The present invention provides a system, method, and composition for delivering effective dosages of an active medicament or medicaments, such as antifungal agents or other antimicrobials, to penetrate the nail layers and to treat the underlying nail bed, the perionychium, or the nail itself. This penetration of the active medicaments is achieved via "etching" the nail surface to provide increased surface area for medicament penetration and absorption, in addition to increased bioadhesion for a drug delivery system.
Of course, the term "nail" is well understood in the art and includes the horny cutaneous plate on the dorsal surface of the distal end of a finger or toe. The term also applies to horny cutaneous surfaces of animals.
Background of the Invention and Background Art 1. Onychomycosis It has been reported that at least 18% of the world population, and approximately 9% of the U.S. population, is afflicted with chronic fungal infections of the fingernails or toenails (onychomycosis). The target sites for the treatment of such infection reside in the nail plate, nail bed, and nail matrix.
Most such infections are caused by obligate aerobic fungal species, usually "dermatophytic" or yeast-like fungi, which infect the nail plate itself. Increased therapies with antineoplastic agents and a continually growing population of immunocompromised individuals, such as those infected with the Human Immunodeficiency Virus (HIV), have shown an increased incidence of systemic morbidity from this persistent disease process. Onychomycosis is a persistent fungal infection of the toenails or fingernails that is unsightly and may affect an individual's quality of life.
The fungus grows on the underside of the nail, causing it to crack, become brittle, and eventually separate from the nail bed.
Technical Field The technical field to which this invention relates includes the field of delivering medicaments to the human or animal nail. Preferred embodiments of the present invention include a composition and method for the transonychial and perionychial administration of medicaments to the human or animal nail or nail area. The present invention provides a system, method, and composition for delivering effective dosages of an active medicament or medicaments, such as antifungal agents or other antimicrobials, to penetrate the nail layers and to treat the underlying nail bed, the perionychium, or the nail itself. This penetration of the active medicaments is achieved via "etching" the nail surface to provide increased surface area for medicament penetration and absorption, in addition to increased bioadhesion for a drug delivery system.
Of course, the term "nail" is well understood in the art and includes the horny cutaneous plate on the dorsal surface of the distal end of a finger or toe. The term also applies to horny cutaneous surfaces of animals.
Background of the Invention and Background Art 1. Onychomycosis It has been reported that at least 18% of the world population, and approximately 9% of the U.S. population, is afflicted with chronic fungal infections of the fingernails or toenails (onychomycosis). The target sites for the treatment of such infection reside in the nail plate, nail bed, and nail matrix.
Most such infections are caused by obligate aerobic fungal species, usually "dermatophytic" or yeast-like fungi, which infect the nail plate itself. Increased therapies with antineoplastic agents and a continually growing population of immunocompromised individuals, such as those infected with the Human Immunodeficiency Virus (HIV), have shown an increased incidence of systemic morbidity from this persistent disease process. Onychomycosis is a persistent fungal infection of the toenails or fingernails that is unsightly and may affect an individual's quality of life.
The fungus grows on the underside of the nail, causing it to crack, become brittle, and eventually separate from the nail bed.
2. Treatment Modalities-Systemic Historical, systemic treatment of these infections has had limited success. Furthermore, physicians are reluctant to treat what has been generally perceived as merely a cosmetic disfiguration with a systemic medication. Negative aspects associated with oral systemic antifiuigal therapy for onychomycosis include their limited success rate, contraindications and drug interactions, toxicity, and the high cost of the medication. Furthermore, a general movement has begun in the medical and scientific communities away from the use of systemic antimicrobial therapy because indiscriminate and widespread use of broad-spectrum antibiotics has lead to an increase in the number of resistant strains of pathogenic microorganisms.
Unfortunately, many fungal nail infections have proven to be very resistant to any type of treatment. Systemic administration of anti-fungal drugs, such as the azoles (ketoconazole, fluconazole) and the allylamines (terbinafine, butenafine), is hindered by limited blood circulation in the nail bed and poor transport to the nail plate, requiring high dosage levels for long periods of time. Such high drug dosages can have adverse side effects, and it has been found that clearance of the infection is often only temporary. Systemic treatment must often be continued indefinitely, thereby also increasing the potential for antimicrobial resistance.
Unfortunately, many fungal nail infections have proven to be very resistant to any type of treatment. Systemic administration of anti-fungal drugs, such as the azoles (ketoconazole, fluconazole) and the allylamines (terbinafine, butenafine), is hindered by limited blood circulation in the nail bed and poor transport to the nail plate, requiring high dosage levels for long periods of time. Such high drug dosages can have adverse side effects, and it has been found that clearance of the infection is often only temporary. Systemic treatment must often be continued indefinitely, thereby also increasing the potential for antimicrobial resistance.
3. Treatment Modalities-Topical Topical therapy for onychomycosis is commonly thought of as the treatment of choice, since it does not lead to adverse systemic effects or drug interactions. However, topical administration of anti-fungal drugs also suffers limitations. This treatment modality has not been effective because antifungal drugs cam-lot readily penetrate the nail plate to reach the infection sites under the nail. The nail plate is a relatively thick structure that inhibits penetration of the drug being applied at a practical rate. Moreover, the topical application of creams, solutions, lotions and gels is often dissipated in relatively short periods of time. Although attempts have been made to incorporate topically active antifungal drugs into film-forming compositions (e.g., nail polishes or lacquers to improve drug persistence), such approaches have not proved entirely satisfactory.
While removal of the nail (nail avulsion) can improve topical drug treatment, several disadvantages to this treatment modality exist which include poor patient acceptance and the ability to maintain a constant supply of the drug to the nail bed.
Although the nail is similar to the stratum corneum of the skin in that it is derived from epidermis, it is composed primarily of highly disulfide-linked keratin and is approximately 100-fold thicker than stratum corneum. The nail contains, as stated previously, three layers, with the dorsal layer being the most electron dense and resistant to antimicrobial penetration. Thus, in order to deliver a sufficient amount of drug into the nail plate, the permeability, in particular the dorsal layer, of the structure to the drug needs to be enhanced.
While removal of the nail (nail avulsion) can improve topical drug treatment, several disadvantages to this treatment modality exist which include poor patient acceptance and the ability to maintain a constant supply of the drug to the nail bed.
Although the nail is similar to the stratum corneum of the skin in that it is derived from epidermis, it is composed primarily of highly disulfide-linked keratin and is approximately 100-fold thicker than stratum corneum. The nail contains, as stated previously, three layers, with the dorsal layer being the most electron dense and resistant to antimicrobial penetration. Thus, in order to deliver a sufficient amount of drug into the nail plate, the permeability, in particular the dorsal layer, of the structure to the drug needs to be enhanced.
4. Human Nail Morphology The nail is similar to the stratum corneum of the skin in that it is derived from epidermis, it is mainly composed of hard, relatively insoluble keratin (highly disulfide-linked); however, it is approximately 100-fold thicker than stratum cornelun. The nail is convex laterally and distally in the horizontal plane and is generally regarded to have three layers: Dorsal, Intermediate and Ventral. The dorsal surface is slightly corrugated, while the ventral surface is deeply grooved for interdigitation with the nail bed, which has a rich vascular and lymphatic supply. The nail plate becomes thinner from its distal free end to its most proximal areas (thickness approx. 0.3-0.7 mm). The structure is composed of dead polyhedral shaped corneocytes, without nuclei or organelles, cemented together and filled with keratin proteins.
5. Etching Dentistry was introduced to the acid-etch technique for tooth restoration in 1955. This idea proposed and subsequently provided for an ideal surface for bonding restorative materials to enamel using 30-40%
phosphoric acid. The present inventor has applied this general principle to the nail plate. Once the nails are etched in accordance with the present invention, the development of microporosities within the nail surface (the dorsal surface, for instance) increases wettability with a resulting increase in surface area and a decrease in contact angle for the drug delivery system or the medicament.
phosphoric acid. The present inventor has applied this general principle to the nail plate. Once the nails are etched in accordance with the present invention, the development of microporosities within the nail surface (the dorsal surface, for instance) increases wettability with a resulting increase in surface area and a decrease in contact angle for the drug delivery system or the medicament.
6. Significance Antifungal drug treatment can be effective topically treating onychomycosis after nail removal. Accordingly, there is a need for a methodology for topical nail fungal treatment that does not require removal of the nail or making holes in the nail, as is disclosed in background art (including U.S. Patent No. 5,947,956, Karell, 1999, discussed below). The present inventor has discovered that nail avulsion or the cutting of holes is the nail is not necessary to achieve optimal drug delivery to the nail plate and the surrounding tissues.
7. Background Art The following references represent background art with respect to the present invention.
Olthoff et al., in EP 440298 Al, disclose the use of sulfur-containing amino acid derivatives in topical preparations for treatment of nail diseases such as onychomycosis.
Kawase et al (EP 472858 A2 Mar. 4, 1992) describe a hair treatment composition containing siloxanes and penetration enhancers such as ammonium thioglycolate, which gives the treated hair a good gloss and a reduced number of hair splits.
Puri (WO 8600013 Al Jan. 3, 1986) discloses that the condition of hair, skin and nails is improved by treatment with an aqueous ammonium thioglycolate solution, followed by treatment with a protein hydrolyzate.
Rothman (WO 8907930 Al Sep. 8, 1989) describes a storage-stable protein-containing composition and a method for treating keratinous tissues. The protein-containing composition contains reducing agents such as ammonium thioglycolate. The composition is said to be useful for conditioning horny keratinous tissues of mammals such as human hair and nail, and the hooves and fur of animals, to improve their strength and appearance and to promote hair and nail growth.
An enhanced transdermal drug permeation in rats has been reported for theophylline [K. Kushida et al., Chem. Pharm. Bull., 32, 1 (1984) 268-274] and insulin [Y. Sun et al., Ann. New York Academy of Sciences, 1990, 596; Y. Sun et al., Proceed. Intern. Sym. Control. Rel. Bioactive Mat., 17 (1990) 202; and J. C. Liu et al., in Drug Permeation Enhancement: Theory and Applications, p247-272, (D. S. Hsieh, Ed.) Marcel Dekker, Inc., 1994] by pretreating the skin with aqueous calcium thioglycolate solution. On the other hand, direct addition of calcium thioglycolate into an ointment containing the calcium salt of indomethacin dramatically decreased the absorption of the drug [T. Ogiso et al., J.
Pharmcobio-Dyn., 9 (1986) 517-525].
Koiulo et. al. (EP 152281 A2 Aug. 21, 1985) describes a transdermal formulation of nicardipine hydrochloride containing urea and thioglycol.
U.S. Pat. No. 5,487,776 discloses an anti-fungal nail lacquer and method for use thereof. The anti-fungal nail lacquer contains, as an anti-finigal agent, griseofulvin. However, this invention has not been effective in treating nail infections due to permeability problems.
The ONYCHOLASERTM (previously cited, U.S. Patent No.
5,947,956, Karell, 1999) relates generally to surgical instruments and more specifically to laser microsurgical instruments for use in cutting holes in tissues or membranes, especially the fingernails and toenails.
U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan disclose various topical formulations for the treatment of nail fungal diseases that may be used in conjunction with the present invention.
Brief Description of the Drawings Figure 1 is an Atomic Force Micrograph of the human dorsal nail surface.
Figure 2 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with tartaric acid (20%).
Figure 3 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with phosphoric acid gel (10%) (60 sec).
Figure 4 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with carbomer 971 P.
Figure 5 is a Scanning Electron Micrograph of the human nail surface (cross-section) untreated.
Figure 6 is a Scanning Electron Micrograph of the human dorsal nail surface (cross-section) treated with tartaric acid (20%) (3 min).
Figure 7 is a chart demonstrating the Mean Roughness Values of the dorsal human nail, untreated and treated as follows: Dorsal = control (untreated); C971 = Carbomer 971P; HPC = Hydroxypropylcellulose;
TTA = Tartaric Acid; and PA = Phosphoric Acid Gel.
Figure 8 is a chart demonstrating diffusion studies of KCZ through the human dorsal nail (a) treated with phosphoric acid gel 10% for 60 sec., and (b) human dorsal nail untreated.
Disclosure of the Invention 1. Brief Summary of the Invention The present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to surface of the nail. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail.
Another embodiment of the present invention is a nail drug delivery composition that comprises an etching agent; and a therapeutically effective amount of a nail medicament. The nail medicament may be, for example, an antifungal composition.
i ,. ...E p Another embodiment of the present invention is directed to a multi-layer, bioadhesive nail medicament nail delivery system, that comprises a matrix layer and a backing layer. Generally speaking, the matrix layer comprises the medicament and the backing layer is impermeable or semi-permeable to ensure unidirectional flow of the medicaments.
The invention further includes a bandage or dressing that is adapted for the topical administration of a medicament to the nail. The bandage will generally include a flexible pad having an impervious backing with an adhesive-coated surface that is adapted to secure the pad to the nail. The pad contains a predetermined amount of a medicament.
Accordingly, in one aspect, the present invention is directed to a nail drug delivery system, comprising: an etching agent; and a nail medicament; wherein said etching agent being present in an amount suitable to increase the surface area of the nail by at least 10 %.
In another aspect, the present invention is directed to a multi-layer, bioadhesive nail medicament delivery system, comprising: a matrix layer that comprises a therapeutically effective amount of a nail medicament, communicates with the surface of the nail, and comprises an etching agent in an amount sufficient to increase the surface of the nail at least 10 %; and a backing layer.
2. Detailed Description of the Invention As stated above, an embodiment of the present invention is a method for delivering an active medicament to a nail plate. The delivery means includes both transonychial and perionychial delivery of the active medicament. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail.
The method of the present invention includes delivering a therapeutically effective amount of active medicament to a diseased nail plate and to the underlying nail bed, wherein the medicament absorption can be increased by first (or concurrently) "etching" the nail surface (usually the dorsal surface) to increase surface area and thus increase drug permeability. Consequently the surrounding skin tissues, including nail bed and matrix via the eponychium and hyponychium, receive the active medicament at an effective rate due to the increased penetration of the active medicament, or by the increased bioadhesion of a delivery device to the surrounding tissues. Preferably, the medicament comprises an antifungal compound.
Etching The medicament delivery process can be achieved via chemical or mechanical etching of the nail surface prior to or during application of the drug delivery system (i.e., the active medicament). The etching is performed to increase the surface area of the nail, which provides an 7a increase in the permeation of the medicament, while in addition providing an increased and more consistent surface area to allow for bioadhesion of a drug delivery system or device.
The etching of this method may be performed chemically with agents such as, but not limited to, inorganic or organic acids, or by mechanical means such as, but not limited to, an etching instrument (such as a laser) or other effective device to alter the surface of the nail that would achieve the purposes of the present invention (i.e., a mini-sandblaster). For example, the microsurgical laser unit of Karrell, U.S.
Patent No. 5,947,956, may be used in the etching step of the methods of the present invention.
Optionally a nail priming technique may be performed during or before the etching step of the method of the present invention. Acceptable primers include dental primers that are used to create better bonding or bioadhesion while etching teeth and applying filling materials. These agents are known to those skilled in the art. Examples of these priming agents include, but are not limited to, maleic and itaconic acid. This invention includes self-etching primers, such as the two organic acids listed above, that allow for the bonding of a drug delivery system and the resulting delivery of the system's medicaments to the nail and/or the perionychium.
In certain embodiments of the present invention, the etching may be performed chemically by etching agents in an etching agent composition. Etching agents of the present invention include, for example, inorganic acids such as phosphoric acids and organic acids such as carboxylic acids and more specifically, tartaric acids. The etching agents may be present in the composition in amounts ranging from about 0.01%
to about 95%, preferably in amounts ranging from about 1 % to about 40%. Preferred etching agents are tartaric acid and phosphoric acid. Most preferably the tartaric acid is present in an amount of about 20%, and the phosphoric acid is present in an amount of about 10%.
The etching agent of the present invention may further comprise a nail medicament. Examples of the nail medicaments include at least one of the following: antifungal or antimicrobial agents, nail growth agents, nail hardening agents, and nail softening agents. Alternatively, at least one of the medicaments listed above (as well as other possible nail medicaments not part of the above list) can be applied to the nail and nail area as a separate medicament composition after the etching process.
The etching agents of the present invention may include the primers listed above. Also, the etching agents can be applied after the primers are applied to the nail.
These aforementioned etching and other agents are to be administered in an amount sufficient to assist enhancement of the permeation of the antifungal or antimicrobial drugs or other medicaments to or through the nail tissue, and/or perionychium, with optimal bioadhesion.
Preferably, after etching, the nail surface will experience an increase in surface area in terms of roughness of from about at least 10%
to about at least 10000%. More preferably, the roughness or surface area increases at least 20%.
Penetration Enhancers Penetration enhancers, or keratolytic agents, known in the art, may be used in a composition of the present invention or as part of the methods of the present invention. to assist in the delivery of the active medicament to the nail plate and surrounding tissues.
Without being bound by theory, a keratolytic agent, i.e., a desquamating agent, helps loosen keratin in the nail and aids in the process of desquarnation or the removal of the upper layers of the damaged or diseased nail. Examples of keratolytic agents include urea, benzoylperoxide, salicylic acid, resorcinol, tretinoin, and others that may be found in "Remington: The Science and Practice of Pharmacy, Nineteenth Edition, pp. 878-879. The optional keratolytic agent will be present in an amount of about 0.01% wt. to about 25% wt., preferably about 0.5 % wt. to about 20% wt., more preferably about 1% wt. to about 20% wt.
Olthoff et al., in EP 440298 Al, disclose the use of sulfur-containing amino acid derivatives in topical preparations for treatment of nail diseases such as onychomycosis.
Kawase et al (EP 472858 A2 Mar. 4, 1992) describe a hair treatment composition containing siloxanes and penetration enhancers such as ammonium thioglycolate, which gives the treated hair a good gloss and a reduced number of hair splits.
Puri (WO 8600013 Al Jan. 3, 1986) discloses that the condition of hair, skin and nails is improved by treatment with an aqueous ammonium thioglycolate solution, followed by treatment with a protein hydrolyzate.
Rothman (WO 8907930 Al Sep. 8, 1989) describes a storage-stable protein-containing composition and a method for treating keratinous tissues. The protein-containing composition contains reducing agents such as ammonium thioglycolate. The composition is said to be useful for conditioning horny keratinous tissues of mammals such as human hair and nail, and the hooves and fur of animals, to improve their strength and appearance and to promote hair and nail growth.
An enhanced transdermal drug permeation in rats has been reported for theophylline [K. Kushida et al., Chem. Pharm. Bull., 32, 1 (1984) 268-274] and insulin [Y. Sun et al., Ann. New York Academy of Sciences, 1990, 596; Y. Sun et al., Proceed. Intern. Sym. Control. Rel. Bioactive Mat., 17 (1990) 202; and J. C. Liu et al., in Drug Permeation Enhancement: Theory and Applications, p247-272, (D. S. Hsieh, Ed.) Marcel Dekker, Inc., 1994] by pretreating the skin with aqueous calcium thioglycolate solution. On the other hand, direct addition of calcium thioglycolate into an ointment containing the calcium salt of indomethacin dramatically decreased the absorption of the drug [T. Ogiso et al., J.
Pharmcobio-Dyn., 9 (1986) 517-525].
Koiulo et. al. (EP 152281 A2 Aug. 21, 1985) describes a transdermal formulation of nicardipine hydrochloride containing urea and thioglycol.
U.S. Pat. No. 5,487,776 discloses an anti-fungal nail lacquer and method for use thereof. The anti-fungal nail lacquer contains, as an anti-finigal agent, griseofulvin. However, this invention has not been effective in treating nail infections due to permeability problems.
The ONYCHOLASERTM (previously cited, U.S. Patent No.
5,947,956, Karell, 1999) relates generally to surgical instruments and more specifically to laser microsurgical instruments for use in cutting holes in tissues or membranes, especially the fingernails and toenails.
U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan disclose various topical formulations for the treatment of nail fungal diseases that may be used in conjunction with the present invention.
Brief Description of the Drawings Figure 1 is an Atomic Force Micrograph of the human dorsal nail surface.
Figure 2 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with tartaric acid (20%).
Figure 3 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with phosphoric acid gel (10%) (60 sec).
Figure 4 is an Atomic Force Micrograph of the human dorsal nail surface that has been treated with carbomer 971 P.
Figure 5 is a Scanning Electron Micrograph of the human nail surface (cross-section) untreated.
Figure 6 is a Scanning Electron Micrograph of the human dorsal nail surface (cross-section) treated with tartaric acid (20%) (3 min).
Figure 7 is a chart demonstrating the Mean Roughness Values of the dorsal human nail, untreated and treated as follows: Dorsal = control (untreated); C971 = Carbomer 971P; HPC = Hydroxypropylcellulose;
TTA = Tartaric Acid; and PA = Phosphoric Acid Gel.
Figure 8 is a chart demonstrating diffusion studies of KCZ through the human dorsal nail (a) treated with phosphoric acid gel 10% for 60 sec., and (b) human dorsal nail untreated.
Disclosure of the Invention 1. Brief Summary of the Invention The present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to surface of the nail. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail.
Another embodiment of the present invention is a nail drug delivery composition that comprises an etching agent; and a therapeutically effective amount of a nail medicament. The nail medicament may be, for example, an antifungal composition.
i ,. ...E p Another embodiment of the present invention is directed to a multi-layer, bioadhesive nail medicament nail delivery system, that comprises a matrix layer and a backing layer. Generally speaking, the matrix layer comprises the medicament and the backing layer is impermeable or semi-permeable to ensure unidirectional flow of the medicaments.
The invention further includes a bandage or dressing that is adapted for the topical administration of a medicament to the nail. The bandage will generally include a flexible pad having an impervious backing with an adhesive-coated surface that is adapted to secure the pad to the nail. The pad contains a predetermined amount of a medicament.
Accordingly, in one aspect, the present invention is directed to a nail drug delivery system, comprising: an etching agent; and a nail medicament; wherein said etching agent being present in an amount suitable to increase the surface area of the nail by at least 10 %.
In another aspect, the present invention is directed to a multi-layer, bioadhesive nail medicament delivery system, comprising: a matrix layer that comprises a therapeutically effective amount of a nail medicament, communicates with the surface of the nail, and comprises an etching agent in an amount sufficient to increase the surface of the nail at least 10 %; and a backing layer.
2. Detailed Description of the Invention As stated above, an embodiment of the present invention is a method for delivering an active medicament to a nail plate. The delivery means includes both transonychial and perionychial delivery of the active medicament. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail.
The method of the present invention includes delivering a therapeutically effective amount of active medicament to a diseased nail plate and to the underlying nail bed, wherein the medicament absorption can be increased by first (or concurrently) "etching" the nail surface (usually the dorsal surface) to increase surface area and thus increase drug permeability. Consequently the surrounding skin tissues, including nail bed and matrix via the eponychium and hyponychium, receive the active medicament at an effective rate due to the increased penetration of the active medicament, or by the increased bioadhesion of a delivery device to the surrounding tissues. Preferably, the medicament comprises an antifungal compound.
Etching The medicament delivery process can be achieved via chemical or mechanical etching of the nail surface prior to or during application of the drug delivery system (i.e., the active medicament). The etching is performed to increase the surface area of the nail, which provides an 7a increase in the permeation of the medicament, while in addition providing an increased and more consistent surface area to allow for bioadhesion of a drug delivery system or device.
The etching of this method may be performed chemically with agents such as, but not limited to, inorganic or organic acids, or by mechanical means such as, but not limited to, an etching instrument (such as a laser) or other effective device to alter the surface of the nail that would achieve the purposes of the present invention (i.e., a mini-sandblaster). For example, the microsurgical laser unit of Karrell, U.S.
Patent No. 5,947,956, may be used in the etching step of the methods of the present invention.
Optionally a nail priming technique may be performed during or before the etching step of the method of the present invention. Acceptable primers include dental primers that are used to create better bonding or bioadhesion while etching teeth and applying filling materials. These agents are known to those skilled in the art. Examples of these priming agents include, but are not limited to, maleic and itaconic acid. This invention includes self-etching primers, such as the two organic acids listed above, that allow for the bonding of a drug delivery system and the resulting delivery of the system's medicaments to the nail and/or the perionychium.
In certain embodiments of the present invention, the etching may be performed chemically by etching agents in an etching agent composition. Etching agents of the present invention include, for example, inorganic acids such as phosphoric acids and organic acids such as carboxylic acids and more specifically, tartaric acids. The etching agents may be present in the composition in amounts ranging from about 0.01%
to about 95%, preferably in amounts ranging from about 1 % to about 40%. Preferred etching agents are tartaric acid and phosphoric acid. Most preferably the tartaric acid is present in an amount of about 20%, and the phosphoric acid is present in an amount of about 10%.
The etching agent of the present invention may further comprise a nail medicament. Examples of the nail medicaments include at least one of the following: antifungal or antimicrobial agents, nail growth agents, nail hardening agents, and nail softening agents. Alternatively, at least one of the medicaments listed above (as well as other possible nail medicaments not part of the above list) can be applied to the nail and nail area as a separate medicament composition after the etching process.
The etching agents of the present invention may include the primers listed above. Also, the etching agents can be applied after the primers are applied to the nail.
These aforementioned etching and other agents are to be administered in an amount sufficient to assist enhancement of the permeation of the antifungal or antimicrobial drugs or other medicaments to or through the nail tissue, and/or perionychium, with optimal bioadhesion.
Preferably, after etching, the nail surface will experience an increase in surface area in terms of roughness of from about at least 10%
to about at least 10000%. More preferably, the roughness or surface area increases at least 20%.
Penetration Enhancers Penetration enhancers, or keratolytic agents, known in the art, may be used in a composition of the present invention or as part of the methods of the present invention. to assist in the delivery of the active medicament to the nail plate and surrounding tissues.
Without being bound by theory, a keratolytic agent, i.e., a desquamating agent, helps loosen keratin in the nail and aids in the process of desquarnation or the removal of the upper layers of the damaged or diseased nail. Examples of keratolytic agents include urea, benzoylperoxide, salicylic acid, resorcinol, tretinoin, and others that may be found in "Remington: The Science and Practice of Pharmacy, Nineteenth Edition, pp. 878-879. The optional keratolytic agent will be present in an amount of about 0.01% wt. to about 25% wt., preferably about 0.5 % wt. to about 20% wt., more preferably about 1% wt. to about 20% wt.
The preferred penetration enhancers are those known in the art for use with onychomycosis medications. For example, ammonium thioglycolate (see EP 472858) may be used. The most preferred penetration enhancers are urea, sodium sulfide and ammonium thioglycolate.
Medicaments The etching agent may comprise at least one nail medicament.
Optionally the medicament may be applied as a separate medicament and/or as part of a separate step in the method of the present invention.
When used herein, the term medicament is understood to include at least one nail medicament or, optionally, a pharmaceutically acceptable salt thereof. The term "pharmaceutically-acceptable" salt means a salt of an active compound that retains the biological effectiveness of the compound and that is not pharmacologically undesirable. A
pharmaceutically-acceptable acid addition salt is one prepared from an organic or inorganic acid that pairs with an appropriate base, e.g., an amino group in the active compound. Inorganic salts derived are from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Organic salts are derived from acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, inaleic acid, furaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, lactic acid and the like.
Additionally, it is understood that the amount, when present in a composition or part of a method, is a therapeutically effective amount.
The preferred medicament of the present invention is one that comprises a therapeutically effective amount of an antifungal compound.
The antifimgal drugs that can be used in the invention include miconazole nitrate, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, ciclopirox, oxiconazole, clotrimazole, terbinafine, butenafine, naftifine, and other antifungal drugs that are available in a topical formulation. The preferred antifungal drugs for use in the process of the invention are itraconazole, ketoconazole, fluconazole, terbinafine and butenafine.
If desired, the topical formulation containing the antifungal drug may include an agent such as hydroxypropyl-.beta.-cyclodextrin that enhances the water-solubility of the antifungal drug, in order to better utilize the aqueous pathway through the nail, as discussed above.
The antifungal formulations of the present invention include those listed in U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan.
The antifimgal compound useful in this invention is one that is effective when applied topically to treat the fungal infection. The amount of the compound present in the composition will be the amount that is therapeutically effective, i.e. an amount that will result in the effective treatment of the onychomycosis when applied in accordance with the instructions described herein.
Further, the term "treatment" covers any treatment of onychomycosis in a mammal, particularly a human, and includes:
(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease, i.e. arresting its development; and (iii) relieving the disease, i.e. causing regression of the disease.
The therapeutically effective amount will vary depending on the subject and the severity of the affliction and may be determined routinely by one of ordinary skill in the art in light of the teaching herein.
Generally, a therapeutically effective amount will be from about 0.1 % (wt.) to about 40% (wt.) based on the total final weight of the composition. Preferably, the amount will be about 0.5% to about 20% by weight and more preferably about 1% to about 10% by weight.
In some embodiments, the composition is a liquid or semisolid, such as a cream, ointment, lotion, lacquer, or gel (preferably a gel) having a solvent in which the antifungal compound (or other nail medicament, when used), or its salt, is dissolved. Thus, the composition will contain at least the antifungal compound, a solvent for the compound, and a gelling agent. Preferably, the composition is water-based, which means that the solvent is preferably water-miscible. In addition, the composition may include a surfactant to aid in the delivery of the antifungal through the nailplate; a film-forming agent; a buffering agent to adjust the pH of the composition; and an adherence-promoting agent to assist in adhering the composition to the nailplate. The composition may be applied directly to the nail or applied in an absorbent pad. Examples of a lacquer of the present invention include the formulations disclosed in U.S. 5,487,776 in combination with the etching agent of the present invention. Further, the present invention includes the nail medicament formulations in combination with the etching agent of the present invention.
Bioadhesive agents may be used to increase the retention and thus the effectiveness of the drug delivery system or medicament. These agents may include a polycarbophil, a carbomer or other bioadhesive agent known to those skilled in the art, such as chitosan or carboxymethyl cellulose. These agents may be incorporated at 0.1 to 25%. Preferably at 1% to 10%.
Additional/Optional Medicaments for use With Methods of the Invention In other embodiments of the present invention, the composition may include medicaments that are traditionally used to treat the nail. These medicaments may include those that are used to soften nails, increase growth of nails, or treat cracked nails. The etching delivery methods of the present invention may be used to deliver these traditional medicaments, either alone or in a combination of medicaments that may or may not include fungal medicaments. Example include urea, sodium sulfide, glycerin and ammonium thioglycolate, to name a few.
As stated above, an embodiment of the present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to surface of the nail. This comprises the transonychial or perionychial administration to and around the nail and if desired, to the surrounding skin. Further, any known medicament composition or formulation may be used as the medicament composition or medicament/etching composition of the present invention.
With respect to applying the medicament to the surface of the nail, any know method of delivering medicaments may be used. For example, see U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan.
The "etching" of the nail plate may occur either prior to or concurrently with the transonychial or perionychial administration to the nail of an effective amount of the medicament. These methods specifically include the application of antifungal or other antimicrobial agents or medicaments to treat the nail and immediate nail area.
The compositions of the present inventions may optionally comprise a bioadhesive agent to enhance permeation of the nail medicament.
Another embodiment of the present invention includes a film (pre-formed or in situ) delivery system adapted for the transonychial or perionychial administration of medication to the nail. This embodiment comprises a predetermined (gel, liquid or film "patch") or custom trimmed device composed of single or multiple layers. One of the layers should be a bioadhesive layer or contain within the matrix layer, a bioadhesive.
Another said layer should be an etching layer or contain within the matrix layer, the etching agent, such as a carboxylic or other acid. The matrix layer may contain a nail medicament discussed above such as an antifungal or antimicrobial drug or drugs, penetration enhancing or keratolytic agents, and/or may be utilized as a rate controlling membrane.
In this embodiment the film preferably includes an impermeable or semi-permeable backing layer to ensure unidirectional flow of the active medicaments, which covers the drug-containing layer. This system should be adhered to the surface of the nail to allow for penetration and/or absorption of the antifungal or antimicrobials drugs to the nail and perionychium.
This embodiment may use the hot-melt extrusion technology for the production of thin, flexible acrylic films for topical drug delivery as described by Aitken-Nichol et al., Pharm Res 13: 804-808 (1996). Also see reference numbers 30-38, below. The active compound may be embedded in a carrier formulation comprised of one or more meltable substances or other functional excipients. The meltable substance may be polymeric materials or low melting point waxes. The bioavailability of the drug substance could be improved when it is dispersed at the molecular level in hot-melt extruded dosage forms. Also see references 39-41.
The film systems of this embodiment may be also be produced by their being cast from organic or aqueous solvents with a casting method known in the art.
Hydroxypropyl cellulose (HPC) and poly(ethylene oxide) (PEO) may be utilized as polymeric carriers for the matrix film formulations.
Medicaments may be incorporated into the film in effective amounts.
Preferred are antifungal compounds and compositions. Most preferred are ketoconazole and terbinafine or butenafine, which may be incorporated in the films at amounts ranging from about 0.1 % to about 40%, preferably about 20% (w/w). Polycarbophil (Noveon AA-1) may be incorporated as a bioadhesive and polyethylene glycol (PEG 3350) as a plasticizer.
Butylated hydroxytoluene (BHT) and propyl gallate may be utilized as antioxidants. Propyl gallate has also been reported to exhibit antifungal properties in addition to its potential synergistic effect with BHT.
Prior to the hot-melt extrusion process, all of the ingredients in the formulation are blended and dried to minimize moisture content. The formulations may then be fed into the hopper and transferred inside the heated barrel by the rotating extruder screw which may be extruded into thin films utilizing a Killion Model KLB-100 extruder equipped with a 6 inch flex-lip die (preferred thickness of the film being about 0.3-1.0 mm).
The films may then be collected in rolls, labeled and sealed in foil-lined 5-mil polyethylene bags (1 mil = 25.4 m or 0.001 inch). The extrusion temperatures will be dependent on the polymeric carriers utilized in the drug delivery system. Screw speed of about 70-80 rpm is preferred (approximate barrel residence time of 90 seconds) for this type of extruder.
The compositions of the present invention may be incorporated into a bandage or dressing adapted for topical administration of the composition to the nail. The compositions may be incorporated into a flexible pad of an adhesive bandage.
References 1. Wessel, S. et al., Hydration of human nails investigated by NIR-FT-Raman spectroscopy. Biochimica et Biophysica Acta 1433:210-216 (1999).
2. Kobayashi, Y., Miyamoto, M., Sugibayashi, K., and Morimoto, Y.
1999. Drug permeation through the three layers of the human nail plate.
JPharm Pharmacol 51:271-278.
3. Gniadecka, O.F., Nielsen, D.H., Christensen, H.C., and Wulf, H.C.
1998. Structure of water, proteins, and lipids in intact human skin, hair and nail. Jlnvestigative Derm 202:393-398.
4. Bertram, J.E.A., and Gosline, J.M. 1987. Functional design of horse hoof keratin the modulation of mechanical properties through hydration effects. J Exp. Biol. 130:121-136.
5. Fraser, R.D.B., and Macrae, T.P. 1980. Molecular structure and mechanical properties of keratins. In Symposia of the Society for Experimental Biology. Cambridge: Cambridge University Press. 211-257.
6. Marshall, R.C. 1983. Characterization of the protein of human hair and nail by electrophoresis. J. Invest. Dermatol. 80:519-524.
7. Baden, H.P., and Laurence, B. 1968. The a-fibrous proteins of epidermis. J. Invest. Dermatol. 51:478-483.
8. Baden, H.P., and Kvedar, J.C. 1991. The Nail. In Physiology, Biochemistry, and Molecular Biology of the Skin. L.A. Goldsmith, editor. Oxford: Oxford University Press. 697-711.
9. Quintanar-Guerrero, D. 1998. The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev Ind Pharm 24.
Medicaments The etching agent may comprise at least one nail medicament.
Optionally the medicament may be applied as a separate medicament and/or as part of a separate step in the method of the present invention.
When used herein, the term medicament is understood to include at least one nail medicament or, optionally, a pharmaceutically acceptable salt thereof. The term "pharmaceutically-acceptable" salt means a salt of an active compound that retains the biological effectiveness of the compound and that is not pharmacologically undesirable. A
pharmaceutically-acceptable acid addition salt is one prepared from an organic or inorganic acid that pairs with an appropriate base, e.g., an amino group in the active compound. Inorganic salts derived are from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Organic salts are derived from acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, inaleic acid, furaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, lactic acid and the like.
Additionally, it is understood that the amount, when present in a composition or part of a method, is a therapeutically effective amount.
The preferred medicament of the present invention is one that comprises a therapeutically effective amount of an antifungal compound.
The antifimgal drugs that can be used in the invention include miconazole nitrate, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, ciclopirox, oxiconazole, clotrimazole, terbinafine, butenafine, naftifine, and other antifungal drugs that are available in a topical formulation. The preferred antifungal drugs for use in the process of the invention are itraconazole, ketoconazole, fluconazole, terbinafine and butenafine.
If desired, the topical formulation containing the antifungal drug may include an agent such as hydroxypropyl-.beta.-cyclodextrin that enhances the water-solubility of the antifungal drug, in order to better utilize the aqueous pathway through the nail, as discussed above.
The antifungal formulations of the present invention include those listed in U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan.
The antifimgal compound useful in this invention is one that is effective when applied topically to treat the fungal infection. The amount of the compound present in the composition will be the amount that is therapeutically effective, i.e. an amount that will result in the effective treatment of the onychomycosis when applied in accordance with the instructions described herein.
Further, the term "treatment" covers any treatment of onychomycosis in a mammal, particularly a human, and includes:
(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease, i.e. arresting its development; and (iii) relieving the disease, i.e. causing regression of the disease.
The therapeutically effective amount will vary depending on the subject and the severity of the affliction and may be determined routinely by one of ordinary skill in the art in light of the teaching herein.
Generally, a therapeutically effective amount will be from about 0.1 % (wt.) to about 40% (wt.) based on the total final weight of the composition. Preferably, the amount will be about 0.5% to about 20% by weight and more preferably about 1% to about 10% by weight.
In some embodiments, the composition is a liquid or semisolid, such as a cream, ointment, lotion, lacquer, or gel (preferably a gel) having a solvent in which the antifungal compound (or other nail medicament, when used), or its salt, is dissolved. Thus, the composition will contain at least the antifungal compound, a solvent for the compound, and a gelling agent. Preferably, the composition is water-based, which means that the solvent is preferably water-miscible. In addition, the composition may include a surfactant to aid in the delivery of the antifungal through the nailplate; a film-forming agent; a buffering agent to adjust the pH of the composition; and an adherence-promoting agent to assist in adhering the composition to the nailplate. The composition may be applied directly to the nail or applied in an absorbent pad. Examples of a lacquer of the present invention include the formulations disclosed in U.S. 5,487,776 in combination with the etching agent of the present invention. Further, the present invention includes the nail medicament formulations in combination with the etching agent of the present invention.
Bioadhesive agents may be used to increase the retention and thus the effectiveness of the drug delivery system or medicament. These agents may include a polycarbophil, a carbomer or other bioadhesive agent known to those skilled in the art, such as chitosan or carboxymethyl cellulose. These agents may be incorporated at 0.1 to 25%. Preferably at 1% to 10%.
Additional/Optional Medicaments for use With Methods of the Invention In other embodiments of the present invention, the composition may include medicaments that are traditionally used to treat the nail. These medicaments may include those that are used to soften nails, increase growth of nails, or treat cracked nails. The etching delivery methods of the present invention may be used to deliver these traditional medicaments, either alone or in a combination of medicaments that may or may not include fungal medicaments. Example include urea, sodium sulfide, glycerin and ammonium thioglycolate, to name a few.
As stated above, an embodiment of the present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to surface of the nail. This comprises the transonychial or perionychial administration to and around the nail and if desired, to the surrounding skin. Further, any known medicament composition or formulation may be used as the medicament composition or medicament/etching composition of the present invention.
With respect to applying the medicament to the surface of the nail, any know method of delivering medicaments may be used. For example, see U.S. Patent Numbers 6,143,794 to Chaudhuri et al.; 6,042,845 to Sun et al.; 6,380,236 to Glassman; 6,224,887 to Samour et al.; 5,993,790 to Strauss; and 6,264,927 to Monahan.
The "etching" of the nail plate may occur either prior to or concurrently with the transonychial or perionychial administration to the nail of an effective amount of the medicament. These methods specifically include the application of antifungal or other antimicrobial agents or medicaments to treat the nail and immediate nail area.
The compositions of the present inventions may optionally comprise a bioadhesive agent to enhance permeation of the nail medicament.
Another embodiment of the present invention includes a film (pre-formed or in situ) delivery system adapted for the transonychial or perionychial administration of medication to the nail. This embodiment comprises a predetermined (gel, liquid or film "patch") or custom trimmed device composed of single or multiple layers. One of the layers should be a bioadhesive layer or contain within the matrix layer, a bioadhesive.
Another said layer should be an etching layer or contain within the matrix layer, the etching agent, such as a carboxylic or other acid. The matrix layer may contain a nail medicament discussed above such as an antifungal or antimicrobial drug or drugs, penetration enhancing or keratolytic agents, and/or may be utilized as a rate controlling membrane.
In this embodiment the film preferably includes an impermeable or semi-permeable backing layer to ensure unidirectional flow of the active medicaments, which covers the drug-containing layer. This system should be adhered to the surface of the nail to allow for penetration and/or absorption of the antifungal or antimicrobials drugs to the nail and perionychium.
This embodiment may use the hot-melt extrusion technology for the production of thin, flexible acrylic films for topical drug delivery as described by Aitken-Nichol et al., Pharm Res 13: 804-808 (1996). Also see reference numbers 30-38, below. The active compound may be embedded in a carrier formulation comprised of one or more meltable substances or other functional excipients. The meltable substance may be polymeric materials or low melting point waxes. The bioavailability of the drug substance could be improved when it is dispersed at the molecular level in hot-melt extruded dosage forms. Also see references 39-41.
The film systems of this embodiment may be also be produced by their being cast from organic or aqueous solvents with a casting method known in the art.
Hydroxypropyl cellulose (HPC) and poly(ethylene oxide) (PEO) may be utilized as polymeric carriers for the matrix film formulations.
Medicaments may be incorporated into the film in effective amounts.
Preferred are antifungal compounds and compositions. Most preferred are ketoconazole and terbinafine or butenafine, which may be incorporated in the films at amounts ranging from about 0.1 % to about 40%, preferably about 20% (w/w). Polycarbophil (Noveon AA-1) may be incorporated as a bioadhesive and polyethylene glycol (PEG 3350) as a plasticizer.
Butylated hydroxytoluene (BHT) and propyl gallate may be utilized as antioxidants. Propyl gallate has also been reported to exhibit antifungal properties in addition to its potential synergistic effect with BHT.
Prior to the hot-melt extrusion process, all of the ingredients in the formulation are blended and dried to minimize moisture content. The formulations may then be fed into the hopper and transferred inside the heated barrel by the rotating extruder screw which may be extruded into thin films utilizing a Killion Model KLB-100 extruder equipped with a 6 inch flex-lip die (preferred thickness of the film being about 0.3-1.0 mm).
The films may then be collected in rolls, labeled and sealed in foil-lined 5-mil polyethylene bags (1 mil = 25.4 m or 0.001 inch). The extrusion temperatures will be dependent on the polymeric carriers utilized in the drug delivery system. Screw speed of about 70-80 rpm is preferred (approximate barrel residence time of 90 seconds) for this type of extruder.
The compositions of the present invention may be incorporated into a bandage or dressing adapted for topical administration of the composition to the nail. The compositions may be incorporated into a flexible pad of an adhesive bandage.
References 1. Wessel, S. et al., Hydration of human nails investigated by NIR-FT-Raman spectroscopy. Biochimica et Biophysica Acta 1433:210-216 (1999).
2. Kobayashi, Y., Miyamoto, M., Sugibayashi, K., and Morimoto, Y.
1999. Drug permeation through the three layers of the human nail plate.
JPharm Pharmacol 51:271-278.
3. Gniadecka, O.F., Nielsen, D.H., Christensen, H.C., and Wulf, H.C.
1998. Structure of water, proteins, and lipids in intact human skin, hair and nail. Jlnvestigative Derm 202:393-398.
4. Bertram, J.E.A., and Gosline, J.M. 1987. Functional design of horse hoof keratin the modulation of mechanical properties through hydration effects. J Exp. Biol. 130:121-136.
5. Fraser, R.D.B., and Macrae, T.P. 1980. Molecular structure and mechanical properties of keratins. In Symposia of the Society for Experimental Biology. Cambridge: Cambridge University Press. 211-257.
6. Marshall, R.C. 1983. Characterization of the protein of human hair and nail by electrophoresis. J. Invest. Dermatol. 80:519-524.
7. Baden, H.P., and Laurence, B. 1968. The a-fibrous proteins of epidermis. J. Invest. Dermatol. 51:478-483.
8. Baden, H.P., and Kvedar, J.C. 1991. The Nail. In Physiology, Biochemistry, and Molecular Biology of the Skin. L.A. Goldsmith, editor. Oxford: Oxford University Press. 697-711.
9. Quintanar-Guerrero, D. 1998. The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev Ind Pharm 24.
10. Gupta, A.K., and Scher, R.K. 1998. Oral antifungal agents for .10 onychomycosis. Lancet 351:541-542.
11. Scher, R.K. 1996. Onychomycosis: a significant medical disorder. I
Am Acad Dermatol 35:S2-5.
Am Acad Dermatol 35:S2-5.
12. Schlefinan, B.S. 1999. Onychomycosis: a compendium of facts and a clinical experience. JFootAnkle Surg 38:290-302.
13. Niewerth, M., and Korting, H.C. 1999. Management of onychomycosis. Drugs 58:283-296.
14. Piraccini, B.M., and Tosti, A. 1999. Drug induced nail disorders:
incidence, management and prognosis. Dur Saf 21:187-201.
incidence, management and prognosis. Dur Saf 21:187-201.
15. Tom, C.M., and Kane, M.P. 1999. Management of toenail onychomycosis. Am JHealth Syst Pharm 56:865-871.
16. Tosti, A., Baran, R., and Piraccini, B.M. 1999. 'Endonyx' Onychomycosis: a new modality of nail invasion by dermatophytes.
Acta Derm Venereol 79:52-53.
Acta Derm Venereol 79:52-53.
17. Debruyne, D., and Coquerel, A. 2001. Pharmacokinetics of Antifungal Agents in Onyclomycosis. Clin Pharmacokinet 40:441-472.
18. Scher, R.K. 1999. Onychomycosis: therapeutic update. J. Am Acad Derinatol 40:S21-26.
19. Whittam, L.R., and Hay, R.J. 1997. The impact of onychomycosis on quality of life. Clin Exp Dermatol 22:87-89.
20. Lubeck, D.P., Patrick, D.L., McNulty, P., Fifer, S.K., and Birnbaum, J.
1993. Quality of life of persons with onychomycosis. Qual Life Res 2:341-348.
1993. Quality of life of persons with onychomycosis. Qual Life Res 2:341-348.
21. Evans, E.G. 1998. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. JAm Acad Dermatol 38:S32-56.
22. Walters, K.A., Flynn, G.L., and Marvel, J.R. 1983. Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol 3 5:2 8 -3 3.
23. Buonocore, M.G. 1955. A simple method of increasing the adhesion of acrylic filling materials to enamel surfaces. JDent Res 34:849-853.
24. Retief, D.H. 1973. Effect of conditioning the enamel surface with phosphoric acid. J Dent Res 52:333-341.
25. Perdigao, J., Frankenberger, R., Rosa, B.T., and Breschi, L. 2000. New trends in dentin/enamel adhesion. Am JDent 13:25-30.
26. Manson-Raherntulla, B., Retief, D.H., and Jamison, H.C. 1984. Effect of concentrations of phosphoric acid on enamel dissolution. JProsthet Dent 51:495-498.
27. 1998. Prompt L-Pop Compomer Adhesive. In Product Dossier ESPE
GmbH. Seefeld, Germany.
GmbH. Seefeld, Germany.
28. 1998. NRC Non-rinse Conditioner. In Technical Manual Dentsply DeTrey. Konstanz, Germany.
29. Aitken-Nichol, C., Zhang, F., and McGinty, J.W. 1996. Hot melt extrusion of acrylic films. Pharm Res 13:804-808.
30. Follonier, N., Doelker, E., and Cole, E.T. 1994. Evaluation of hot-melt extrusion as a new technique for the production of polymer-based pellets for sustained release capsules containing high loadings of freely soluble drugs. Drug Dev Ind Pharm 20: 1323-1339.
31. Follonier, N., Doelker, E., and Cole, E.T. 1995. Various ways of modulating the release of diltiazern hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J
Controlled Release 36:243-250.
Controlled Release 36:243-250.
32. Grunhagen, H.H., and Muller, 0. 1995. Melt extrusion technology.
Pharmaceutical Manufacturing International: 166-170.
Pharmaceutical Manufacturing International: 166-170.
33. McGinity, J.W., Zhang, F., Repka, M.A., and Koleng, J.J. 2000.
Thermal Processing of Pharmaceutical Powders. Pharm. Tech. Japan 16:897-913.
Thermal Processing of Pharmaceutical Powders. Pharm. Tech. Japan 16:897-913.
34. Repka, M.A., and McGinity, J.W. 2000. Physical-mechanical, moisture absorption and bioadhesive properties of hydroxypropylcellulose hot-melt extruded films. Biomaterials 21:1509-1517.
35. Repka, M.A., and McGinity, J.W. 2000. Influence of Vitamin E TPGS
on the properties of hydrophilic films produced by hot-melt extrusion.
Int J Pharm 202:63-70.
on the properties of hydrophilic films produced by hot-melt extrusion.
Int J Pharm 202:63-70.
36.Repka, M.A., and McGinity, J.W. 2001. Bioadhesive Properties of Hydroxypropylcellulose Topical Films Produced by Hot-Melt Extrusion. J Control Release 70:341-351.
37. Repka, M.A., and McGinity, J.W. 2001. Influence of Chlorpheniramine Maleate on Topical Films Produced by Hot-Melt Extrusion. Pharni Dev Tech 6:295-302.
38. Repka, M.A., McGinity, J.W., Zhang, F., and Koleng, J.J. 2001. Hot-Melt Extrusion Technology. In Encyclopedia of Pharmaceutical Technology. J. Swarbrick, and J. Boylan, editors. New York: Marcel Dekker.
39. Repka, M.A., Gerding, T.G., Repka, S.L., and McGinity, J.W. 1999.
Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot-melt extrusion. Drug Dev Ind Pharm 25:625-633.
Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot-melt extrusion. Drug Dev Ind Pharm 25:625-633.
40. Zhang, F., and McGinity, J.W. 1999. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharrrz. Dev. Technol. 4:241-250.
41. Sato, H., and Miyagawa, Y. 1997. Dissolution Mechanism of Diclofenac Sodium Wax Matrix Granules. JPharin Sci 86:929-934.
42. Thorndike, E.E. 1968. A microscopic study of the marmoset claw and nail. Am. J. Phys. Anthropol. 28:247-26 1.
43. Montagna, W., and Paraldcal, P.F. 1974. Nails in the structure and function of skin. New York: Academic Press.
44. Mauro, J., Lumpkin, L.R., and Dantzig, P.I. 1975. Scanning electron microscopy of psoriatic nail pits. NY State J. Med. 75:339-342.
45. Germain, H., Barran, W., and Plewig, G. 1980. Morphology of corneocytes from human nail plates. J. Invest. Dermatol. 74:115-118.
46. Baden, H.P., and Kibilus, J. 1984. A comparative study of the immunologic properties of hoof and nail fibrous proteins. J. Invest.
Derinatol. 83:327-331.
Derinatol. 83:327-331.
47. Baden, H.P. 1987. The Nail. In Diseases of the hair and nail: Year Book Medical Publishers.
48. Repka, M.A., O'Haver, J., See, C.-H., Gutta, K., and Munjal, M. 2002.
Nail morphology studies as assessments for onychomycosis treatment modalities. Int JPharm 245:25-36.
Nail morphology studies as assessments for onychomycosis treatment modalities. Int JPharm 245:25-36.
49. Song, Y., Li, S.K., Peck, K.D., Zhu, H., Ghanem, A.H., and Higuchi, W.I. 2002. Human epidermal membrane constant conductance iontophoresis: alternating current to obtain reproducible enhanced permeation and reduced lag times of a nonionic polar permeant. Int J
Pharm 232:45-57.
Pharm 232:45-57.
50. Rowe, R.C. 1980. Rate effects in the measurement of the adhesions of film coatings to tablet surfaces. JPharm Pharinacol 32:214-215.
51. Repka, M.A., Prodduturi, S., and Stodghill, S.P. 2002. Production and characterization of hot-melt extruded films containing clotrimazole.
Drug Dev Ind Pharm Submitted September 2002.
Drug Dev Ind Pharm Submitted September 2002.
52. Weller, P.J. 2000. Propyl gallate. In Handbook of Pharmaceutical Excipients. K.H. Arthur, editor. Washington, D.C.: American Pharmaceutical Association. 447-449.
53. Chen, X., Young, T.J., Sarkari, M., Williams, R.O., and Johnston, K.P.
2002. Preparation of cyclosporin A nanoparticles by evaporative precipitation into aqueous solution. IntJPharm 242:3-14.
Best Mode for Carrying out the Invention The best mode for carrying out the invention as contemplated by the Applicant at the time of filing this Application is evident from the Examples listed below.
The following examples serve only to illustrate the present invention. They are representative in nature and should not by construed in any way as narrowing or limiting the scope of the invention as claimed.
Example 1 After etching the dorsal surface of the nail with a 10% phosphoric acid, carbomer hydro alcoholic gel, the following hot-melt extruded composition is applied to the nail:
Drug/Chemical (% w/w) Antifungal Composition Hydroxypropyl cellulose (Avg MW: 850,000) 41.23 Hydroxypropyl cellulose (Avg MW: 350,000) 12 Polyethylene Oxide (Avg MW: 200,000) 20.5 Propylparaben NF 0.02 Methylparaben NF 0.20 Butylated Hydroxytoluene NF 0.05 Polycarbophil (Noveon*AA-1) 4.00 Tartaric Acid 2.0 Polyethylene glycol 3350 10.0 Ketocoiiazole, USP 10.0 Example 2 Example 2 is an in situ film formulation for the etching and concomitant nail softening nail composition.
Drug/Chemical (% w/w) Etching/Nail Softener Hydroxypropyl cellulose (Avg MW: 80,000) 21.78 Polyethylene glycol 3350 15 Ethanol (95%) 30 Propylparaben NF 0.02 Methylparaben NF 0.20 Urea 10 Carbomer 971P 3.9 Lactic Acid 4.0 Triethanolamine (TEA) 0.1 Purified Water 15.0 Example 3 Example 3 is an example of chemically etching a human nail and examining the etched nail's morphology. In this example, a 20% tartaric acid (TTA) solution is applied to human nail samples for 120 seconds as a chemical etching agent. Atomic Force Microscopy (AFM), scanning electron microscopy (SEM), and polarized light microscopy (PLM) were utilized to visualize nail morphology and topographical changes in the nail samples subject to the chemical agent. A review of the AFM micrographs *Trade Mark reveal significant changes in topography to the dorsal layer as a result of the chemical agent being applied. Roughness scores, as determined by Nanoscope TM IIla software, recorded a significant change in surface roughness of the etched nail when compared to the control (no treatment) (112.2 vs. 85.0 rim, respectfully). See Figure 7.
Example 4 Example 3 is repeated, but with human nail samples treated with a phosphoric acid (10%) gel for 60 seconds. The roughness increase is about two-fold greater vs. the control (147.8 vs. 85.0 nm, respectfully). See Figure 7.
Example 5 Example 5 examines bioadhesion, and demonstrates determining and comparing the bioadhesive properties of hot-melt extruded polymeric film systems for onychomycosis on the human nail not treated and treated with a surface etching method of the present invention. The film systems containing the antifungal medicament ketoconazole are prepared using a single screw Killion extruder (KLB-100). The film has the following content:
Drug/Chemical (% w/w) Antifungal Composition Hydroxypropyl cellulose (Avg MW: 850,000) 36.23 Hydroxypropyl cellulose (Avg MW: 350,000) 18 Polyethylene Oxide (Avg MW: 200,000) 23.5 Propylparaben NF 0.02 Methylparaben NF 0.20 Butylated Hydroxytoluene NF 0.05 Polycarbophil (Noveon* AA-1) 5.00 Tartaric Acid 2.0 Polyethylene glycol 3350 5.0 Ketoconazole, USP 10.0 The extruded films are applied to human nail samples, in-vitro.
Tensile and peel tests of the film are performed on the nail substrates using a Texture Analyzer (TA.XT2i) equipped with Texture Expert Software.
Bioadhesive profiles of the films are determined from the recorded data.
The instrument variables used were contact time and speed of withdrawal of the probe from the tissue. The nail samples tested are either non-treated *Trade Mark (control) or treated with phosphoric acid gel 10% (PA), a chemical etching agent of the present invention. Peak adhesion force (PAF) and area under curve (AUC) are determined for the bioadhesion testing.
PAF and AUC are determined to be greater for human nail samples treated with the PA gel compared to that of the control for each of the instrument variables studied. Utilizing the peel test, (contact time of 10 seconds), the PAF and AUC are 3.9 N and 3.9 mJ respectively, for the treated samples compared to that of the control (1.6 N and 2.6 mJ). In addition the tensile test resulted in a PAF of 4.1 N for the control vs. 5.6 N
for the PA treated nail. Without being bound by theory, the greater peak force and AUC recorded for the etched nail to the film is a result of the microporosity and increased surface area that allows for more effective polymer chain interdiffusion. The nail samples treated in accordance with the present invention increase PAF and AUC values of both peel and tensile tests compared to that of the untreated nail.
Example 6 Example 6 examines permeability of the medicament into the nail.
For this Example, ketoconazole is utilized as a model drug to perform permeability studies. The drug is dissolved in two different media for testing which functioned as the donor solution. The first is an isotonic phosphate buffer solution (pH 7.2) with 0.5% Brij* 58 as a solubilizer. The second is an 80:20 methanol/water solution buffered to pH 7.2. The receptor media is the same as the donor media without dissolved drug in both cases.
A system employing 9 modified glass Franz diffusion cells is used.
Full thickness nail plates are sandwiched between two polypropylene adapters with an O-ring and were mounted on the individual cells with the dorsal nail plate facing the donor compartment (receptor volume 5.2 ml;
donor surface area 0.5 cm2). The receptor fluid is maintained at 37 +
0.5 C and is continuously stirred with a magnetic bar. The donor solutions are applied to the dorsal nail surface following a one hour hydration period. Samples of the receptor phase are withdrawn at predetermined time intervals (for up to 48 hours) and immediately replaced with fresh *Trade Mark donor solution. Analysis of the samples is corrected for previous drug removed. The receptor and donor compartments are sealed with a sheet of aluminum foil and wrapped with parafilm*. The hermeticity of the system was continuously monitored. Drug content in the receptor media is determined using high performance liquid chromatography.
The ketoconazole (phosphate buffer/Brij* 58) that permeats the unetched nail plates after 48 hours is 446 ( 51) g/cm2. However, total permeation of drug through the etched nail plates after the same time interval is 1,873 (+ 155) .ig/cm2, or approximately a 4-fold difference. The same directional difference is recorded with the buffered methanol/water solution of ketoconazole. The nail etched in accordance with the present invention exhibits an approximate 3-fold greater total permeation of drug (6,191 + 323.3 g/cm2) than that of the nonetched nail (2,497 + 237 g/cm2). Also, see Figure 8.
Example 7 A phosphoric acid carbomer, hydroalcoholic gel at 10%, is applied to the dorsal nail surface for 60 seconds, then washed for 1 minute with approximately 100ml of purified water and air dried at room temperature for approximately 5 minutes. Afterward, a composition of Example 1 is applied to the nail with light pressure until the film system was not tacky to touch. The film delivery system is then left on the nail for a period of 48 hours.
Industrial Applicability It is desirable to provide an effective system and composition for topically treating nail fungal infections. The present invention provides such treatment methods and compositions for delivering effective dosages of a medicament to the nail area, underlying nail bed, perionychium, or to the nail itself. The methods and compositions of the present invention may be used to treat fungal infections such as onychomycosis. Morphology studies of the nail via scanning electron and atomic force microscopy have revealed a significant change in surface topography (both qualitative and semi-quantitative) when the dorsal nail plate was subjected to the etching *Trade Mark methods of the present invention. Additionally, the methods of the present invention provide increased permeability of a model antimycotic drug through the nail.
The benefits of the present invention are significant because, among other things, topical therapy for onychomycosis is considered by many in the field to be the treatment of choice for this disease process, since it does not lead to adverse systemic effects or drug interactions.
Before the present invention, topical therapy was more difficult because of the physical properties of the nail.
The invention thus being described, it would be obvious to one of ordinary skill in the art that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one of ordinary skill in the art are intended to be included within the scope of this invention.
2002. Preparation of cyclosporin A nanoparticles by evaporative precipitation into aqueous solution. IntJPharm 242:3-14.
Best Mode for Carrying out the Invention The best mode for carrying out the invention as contemplated by the Applicant at the time of filing this Application is evident from the Examples listed below.
The following examples serve only to illustrate the present invention. They are representative in nature and should not by construed in any way as narrowing or limiting the scope of the invention as claimed.
Example 1 After etching the dorsal surface of the nail with a 10% phosphoric acid, carbomer hydro alcoholic gel, the following hot-melt extruded composition is applied to the nail:
Drug/Chemical (% w/w) Antifungal Composition Hydroxypropyl cellulose (Avg MW: 850,000) 41.23 Hydroxypropyl cellulose (Avg MW: 350,000) 12 Polyethylene Oxide (Avg MW: 200,000) 20.5 Propylparaben NF 0.02 Methylparaben NF 0.20 Butylated Hydroxytoluene NF 0.05 Polycarbophil (Noveon*AA-1) 4.00 Tartaric Acid 2.0 Polyethylene glycol 3350 10.0 Ketocoiiazole, USP 10.0 Example 2 Example 2 is an in situ film formulation for the etching and concomitant nail softening nail composition.
Drug/Chemical (% w/w) Etching/Nail Softener Hydroxypropyl cellulose (Avg MW: 80,000) 21.78 Polyethylene glycol 3350 15 Ethanol (95%) 30 Propylparaben NF 0.02 Methylparaben NF 0.20 Urea 10 Carbomer 971P 3.9 Lactic Acid 4.0 Triethanolamine (TEA) 0.1 Purified Water 15.0 Example 3 Example 3 is an example of chemically etching a human nail and examining the etched nail's morphology. In this example, a 20% tartaric acid (TTA) solution is applied to human nail samples for 120 seconds as a chemical etching agent. Atomic Force Microscopy (AFM), scanning electron microscopy (SEM), and polarized light microscopy (PLM) were utilized to visualize nail morphology and topographical changes in the nail samples subject to the chemical agent. A review of the AFM micrographs *Trade Mark reveal significant changes in topography to the dorsal layer as a result of the chemical agent being applied. Roughness scores, as determined by Nanoscope TM IIla software, recorded a significant change in surface roughness of the etched nail when compared to the control (no treatment) (112.2 vs. 85.0 rim, respectfully). See Figure 7.
Example 4 Example 3 is repeated, but with human nail samples treated with a phosphoric acid (10%) gel for 60 seconds. The roughness increase is about two-fold greater vs. the control (147.8 vs. 85.0 nm, respectfully). See Figure 7.
Example 5 Example 5 examines bioadhesion, and demonstrates determining and comparing the bioadhesive properties of hot-melt extruded polymeric film systems for onychomycosis on the human nail not treated and treated with a surface etching method of the present invention. The film systems containing the antifungal medicament ketoconazole are prepared using a single screw Killion extruder (KLB-100). The film has the following content:
Drug/Chemical (% w/w) Antifungal Composition Hydroxypropyl cellulose (Avg MW: 850,000) 36.23 Hydroxypropyl cellulose (Avg MW: 350,000) 18 Polyethylene Oxide (Avg MW: 200,000) 23.5 Propylparaben NF 0.02 Methylparaben NF 0.20 Butylated Hydroxytoluene NF 0.05 Polycarbophil (Noveon* AA-1) 5.00 Tartaric Acid 2.0 Polyethylene glycol 3350 5.0 Ketoconazole, USP 10.0 The extruded films are applied to human nail samples, in-vitro.
Tensile and peel tests of the film are performed on the nail substrates using a Texture Analyzer (TA.XT2i) equipped with Texture Expert Software.
Bioadhesive profiles of the films are determined from the recorded data.
The instrument variables used were contact time and speed of withdrawal of the probe from the tissue. The nail samples tested are either non-treated *Trade Mark (control) or treated with phosphoric acid gel 10% (PA), a chemical etching agent of the present invention. Peak adhesion force (PAF) and area under curve (AUC) are determined for the bioadhesion testing.
PAF and AUC are determined to be greater for human nail samples treated with the PA gel compared to that of the control for each of the instrument variables studied. Utilizing the peel test, (contact time of 10 seconds), the PAF and AUC are 3.9 N and 3.9 mJ respectively, for the treated samples compared to that of the control (1.6 N and 2.6 mJ). In addition the tensile test resulted in a PAF of 4.1 N for the control vs. 5.6 N
for the PA treated nail. Without being bound by theory, the greater peak force and AUC recorded for the etched nail to the film is a result of the microporosity and increased surface area that allows for more effective polymer chain interdiffusion. The nail samples treated in accordance with the present invention increase PAF and AUC values of both peel and tensile tests compared to that of the untreated nail.
Example 6 Example 6 examines permeability of the medicament into the nail.
For this Example, ketoconazole is utilized as a model drug to perform permeability studies. The drug is dissolved in two different media for testing which functioned as the donor solution. The first is an isotonic phosphate buffer solution (pH 7.2) with 0.5% Brij* 58 as a solubilizer. The second is an 80:20 methanol/water solution buffered to pH 7.2. The receptor media is the same as the donor media without dissolved drug in both cases.
A system employing 9 modified glass Franz diffusion cells is used.
Full thickness nail plates are sandwiched between two polypropylene adapters with an O-ring and were mounted on the individual cells with the dorsal nail plate facing the donor compartment (receptor volume 5.2 ml;
donor surface area 0.5 cm2). The receptor fluid is maintained at 37 +
0.5 C and is continuously stirred with a magnetic bar. The donor solutions are applied to the dorsal nail surface following a one hour hydration period. Samples of the receptor phase are withdrawn at predetermined time intervals (for up to 48 hours) and immediately replaced with fresh *Trade Mark donor solution. Analysis of the samples is corrected for previous drug removed. The receptor and donor compartments are sealed with a sheet of aluminum foil and wrapped with parafilm*. The hermeticity of the system was continuously monitored. Drug content in the receptor media is determined using high performance liquid chromatography.
The ketoconazole (phosphate buffer/Brij* 58) that permeats the unetched nail plates after 48 hours is 446 ( 51) g/cm2. However, total permeation of drug through the etched nail plates after the same time interval is 1,873 (+ 155) .ig/cm2, or approximately a 4-fold difference. The same directional difference is recorded with the buffered methanol/water solution of ketoconazole. The nail etched in accordance with the present invention exhibits an approximate 3-fold greater total permeation of drug (6,191 + 323.3 g/cm2) than that of the nonetched nail (2,497 + 237 g/cm2). Also, see Figure 8.
Example 7 A phosphoric acid carbomer, hydroalcoholic gel at 10%, is applied to the dorsal nail surface for 60 seconds, then washed for 1 minute with approximately 100ml of purified water and air dried at room temperature for approximately 5 minutes. Afterward, a composition of Example 1 is applied to the nail with light pressure until the film system was not tacky to touch. The film delivery system is then left on the nail for a period of 48 hours.
Industrial Applicability It is desirable to provide an effective system and composition for topically treating nail fungal infections. The present invention provides such treatment methods and compositions for delivering effective dosages of a medicament to the nail area, underlying nail bed, perionychium, or to the nail itself. The methods and compositions of the present invention may be used to treat fungal infections such as onychomycosis. Morphology studies of the nail via scanning electron and atomic force microscopy have revealed a significant change in surface topography (both qualitative and semi-quantitative) when the dorsal nail plate was subjected to the etching *Trade Mark methods of the present invention. Additionally, the methods of the present invention provide increased permeability of a model antimycotic drug through the nail.
The benefits of the present invention are significant because, among other things, topical therapy for onychomycosis is considered by many in the field to be the treatment of choice for this disease process, since it does not lead to adverse systemic effects or drug interactions.
Before the present invention, topical therapy was more difficult because of the physical properties of the nail.
The invention thus being described, it would be obvious to one of ordinary skill in the art that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one of ordinary skill in the art are intended to be included within the scope of this invention.
Claims (15)
1. A nail drug delivery system, comprising:
an etching agent comprising about 20% tartaric acid or about 10% phosphoric acid or salts thereof; and a nail medicament;
wherein said etching agent being present in an amount selected to increase the surface area of the nail by at least 10 %.
an etching agent comprising about 20% tartaric acid or about 10% phosphoric acid or salts thereof; and a nail medicament;
wherein said etching agent being present in an amount selected to increase the surface area of the nail by at least 10 %.
2. The drug delivery system of claim 1, further comprising at least one of a bioadhesive agent, nail penetration enhancer, or a keratolytic altering agent.
3. The drug delivery system of claim 1, further comprising at least one of a nail growth agent, a nail hardening agent, a nail softening agent, a nail penetration enhancer, a keratolytic agent or a bioadhesive agent.
4. The drug delivery system of claim 1, wherein the medicament is an antifungal compound.
5. The drug delivery system of claim 4, wherein the antifungal compound is selected from the group consisting of miconazole nitrate, ketoconazole, itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, ciclopirox, oxiconazole, clotrimazole, terbinafine, butenafine, and naftifine.
6. A multi-layer, bioadhesive nail medicament delivery system, comprising:
a matrix layer that comprises a nail medicament, communicates with the surface of a nail, and comprises an etching agent in an amount selected to increase the surface of the nail at least 10 %; and a backing layer wherein said etching agent comprises about 20% tartaric acid or 10% phosphoric acid or salts thereof.
a matrix layer that comprises a nail medicament, communicates with the surface of a nail, and comprises an etching agent in an amount selected to increase the surface of the nail at least 10 %; and a backing layer wherein said etching agent comprises about 20% tartaric acid or 10% phosphoric acid or salts thereof.
7. The nail medicament delivery system of claim 6, wherein the backing layer is adapted to ensure unidirectional flow of said medicament.
8. The nail medicament delivery system of claim 7, the system being in the form of a bandage or dressing.
9. The nail medicament delivery system of claim 7, wherein the backing layer is part of an adhesive strip, and the matrix layer is in the form of a flexible pad that communicates with the strip.
10. The nail medicament delivery system of claim 7, wherein the matrix layer is in turn composed of multiple layers, having an etching layer that comprises an etching agent and a bioadhesive layer.
11. Use of the drug delivery system as defined in any one of claims 1 to 5 for treating a fungal infection of a fingernail or toenail.
12. Use of the system as defined in any one of claims 6 to 10 for treating a fungal infection of a fingernail or toenail.
13. Use of the drug delivery system as defined in any one of claims 1 to 5 for delivering a medicament to a nail plate or a nail bed.
14. Use of the system as defined in any one of claims 6 to 10 for delivering a medicament to a nail plate or a nail bed.
15. The drug delivery system as claimed in any one of claims 1 to 5 wherein said etching agent and said nail medicament are provided as part of a composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33041501P | 2001-10-22 | 2001-10-22 | |
US60/330,415 | 2001-10-22 | ||
PCT/US2002/033694 WO2003047503A2 (en) | 2001-10-22 | 2002-10-22 | Delivery of medicaments to the nail |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2468539A1 CA2468539A1 (en) | 2003-06-12 |
CA2468539C true CA2468539C (en) | 2013-01-08 |
Family
ID=23289669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2468539A Expired - Lifetime CA2468539C (en) | 2001-10-22 | 2002-10-22 | Delivery of medicaments to the nail |
Country Status (4)
Country | Link |
---|---|
US (1) | US7959904B2 (en) |
AU (1) | AU2002364893A1 (en) |
CA (1) | CA2468539C (en) |
WO (1) | WO2003047503A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2372113C2 (en) * | 2003-07-14 | 2009-11-10 | Пауэр Пэйпер Лтд. | Method, apparatus and kit for onychomycosis treatment with using electrokinetic mass transport |
BRPI0418589A (en) | 2003-12-08 | 2008-01-29 | Bentley Pharmaceuticals Inc | pharmaceutical compositions and methods for insulin treatment |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
KR20070095921A (en) * | 2004-12-10 | 2007-10-01 | 탈리마 테라퓨틱스 인코포레이티드 | Compositions and methods for treating conditions of the nail unit |
US8277495B2 (en) | 2005-01-13 | 2012-10-02 | Candela Corporation | Method and apparatus for treating a diseased nail |
US20090215888A1 (en) * | 2006-03-02 | 2009-08-27 | Singh Jagat | Topical nail formulation |
US20080107735A1 (en) * | 2006-11-02 | 2008-05-08 | Gyurik Robert J | Macrocyclic formulations for transmembrane drug delivery |
WO2008105038A1 (en) * | 2007-02-23 | 2008-09-04 | Nichiban Company Limited | Adhesive patch for mycosis |
US20080261986A1 (en) * | 2007-03-30 | 2008-10-23 | Friden Phillip M | Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug |
US20100291182A1 (en) * | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
EP2229980B1 (en) * | 2009-03-16 | 2015-08-12 | Nuvolase, Inc. | Treatment of microbiological pathogens in a toe nail with antimicrobial light |
GB0907553D0 (en) | 2009-05-01 | 2009-06-10 | Insense Ltd | Treatment of human or animal body surface infection |
US8814922B2 (en) * | 2009-07-22 | 2014-08-26 | New Star Lasers, Inc. | Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
EP2575829A4 (en) * | 2010-06-07 | 2014-04-30 | Topical Pharma Ab | Kit for the treatment of onychomycosis by nitric oxide |
US9034240B2 (en) | 2011-01-31 | 2015-05-19 | Arsenal Medical, Inc. | Electrospinning process for fiber manufacture |
US8968626B2 (en) | 2011-01-31 | 2015-03-03 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
US9194058B2 (en) | 2011-01-31 | 2015-11-24 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
JP6150802B2 (en) | 2011-09-05 | 2017-06-21 | クール セラピューティクス, インコーポレイテッド | Stomach, skin, and peritoneal delivery of frozen mist to induce hyperthermia |
US8993831B2 (en) | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
RU2015143995A (en) | 2013-03-14 | 2017-04-20 | Халлюкс, Инк. | METHOD FOR TREATING INFECTIONS, DISEASES OR DISEASES OF THE NAIL LODGE |
US11358002B2 (en) | 2014-05-29 | 2022-06-14 | Raymond R. Blanche | Method and apparatus for non-thermal nail, foot, and hand fungus treatment |
AU2015266676A1 (en) | 2014-05-29 | 2016-12-15 | New Skin Therapies, LLC, d/b/a/ NST Consulting, LLC | Method and apparatus for non-thermal nail, foot, and hand fungus treatment |
AU2018399215A1 (en) * | 2018-01-02 | 2020-07-09 | Nal Pharmaceutical Group Limited | Liquid dosage form for topical application |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4180058A (en) * | 1978-08-15 | 1979-12-25 | Jacob Brem | Method of treating pathological conditions of the nail |
US4637930A (en) | 1984-02-08 | 1987-01-20 | Yamanouchi Pharmaceutical Co, Ltd. | Transdermal formulation of nicardipine hydrochloride |
GB2160419B (en) | 1984-06-08 | 1990-02-14 | Crestol Ltd | Treatment of hair, skin and nails |
AU614832B2 (en) | 1988-03-04 | 1991-09-12 | Ciro's Touch, Ltd. | Storage-stable compositions and methods for treating keratinous tissue |
IL97012A0 (en) | 1990-01-30 | 1992-03-29 | Gist Brocades Nv | Topical preparations for treating human nails |
EP0472858B2 (en) | 1990-07-04 | 2000-03-15 | Kao Corporation | Hair treatment composition |
US5487776A (en) * | 1994-03-17 | 1996-01-30 | Nimni; Marcel | Anti-fungal nail lacquer and method therefor |
US5696164A (en) * | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
US5947956A (en) * | 1997-11-04 | 1999-09-07 | Karell; Manuel Leon | Laser apparatus for making holes and etchings |
ATE238751T1 (en) * | 1998-02-09 | 2003-05-15 | Macrochem Corp | ANTI-FUNGAL NAIL POLISH |
US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
NZ506925A (en) * | 1998-04-17 | 2003-03-28 | Bertek Pharm Inc | Topical formulations for the treatment of nail fungal diseases |
US6264927B1 (en) * | 1998-08-27 | 2001-07-24 | Elmer P. Monahan | Topical solution and method for the treatment of nail fungus |
US6159977A (en) * | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
US6281239B1 (en) * | 2000-04-12 | 2001-08-28 | Bradley Pharmeaceuticals, Inc. | Method of treating onychomycosis |
US6413555B1 (en) * | 2000-12-29 | 2002-07-02 | All Nature's Solutions L.L.C. | Composition and method of treating nail infections |
US6664292B2 (en) * | 2001-06-04 | 2003-12-16 | Mark H. Bogart | Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
-
2002
- 2002-10-22 CA CA2468539A patent/CA2468539C/en not_active Expired - Lifetime
- 2002-10-22 AU AU2002364893A patent/AU2002364893A1/en not_active Abandoned
- 2002-10-22 WO PCT/US2002/033694 patent/WO2003047503A2/en not_active Application Discontinuation
-
2004
- 2004-04-22 US US10/830,730 patent/US7959904B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2468539A1 (en) | 2003-06-12 |
AU2002364893A1 (en) | 2003-06-17 |
WO2003047503A3 (en) | 2003-12-18 |
US20040197280A1 (en) | 2004-10-07 |
WO2003047503A2 (en) | 2003-06-12 |
US7959904B2 (en) | 2011-06-14 |
AU2002364893A8 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2468539C (en) | Delivery of medicaments to the nail | |
JP5850889B2 (en) | Adhesive skin-forming formulation for skin delivery of drugs and method of using the same | |
JP5290582B2 (en) | Pharmaceutical composition for nail | |
TWI232756B (en) | Nail lacquer composition for drug delivery | |
US11324705B2 (en) | Transdermal drug delivery system | |
ATE258426T1 (en) | COMPOSITIONS AND METHODS FOR THE TOPICAL APPLICATION OF ACTIVE INGREDIENTS | |
JP5174671B2 (en) | Antifungal composition | |
JP3803393B2 (en) | Nail ringworm treatment composition | |
JPH08188527A (en) | Sheet-like pack agent | |
JP4359140B2 (en) | Formulation for removing abnormal keratinous substances | |
AU2019349935B2 (en) | Transdermal drug delivery system | |
WO2011061155A1 (en) | Antifungal formulations and their use | |
Al-Jarsha et al. | A Review on Film Forming Drug Delivery Systems | |
MX2008004132A (en) | Antifungal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20221024 |